Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies

Archives of Dermatological Research

Volumn 298, Issue 10, 2007, Pages 469-477

  Utikal, Jochen ^a   Schadendorf, Dirk ^a,b   Ugurel, Selma ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Biomarker; Immunohistochemistry; Prognosis; Serum; Skin cancer

Indexed keywords

ALBUMIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLEIOTROPHIN; PROTEIN BCL XL; RETINOBLASTOMA PROTEIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CELL PROLIFERATION; CUTANEOUS T CELL LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROLOGY; SKIN CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

CARCINOMA, SQUAMOUS CELL; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MELANOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847127827     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-006-0726-5     Document Type: Review

References (94)

1. Acland K, Evans AV, Abraha H, Healy CM, Roblin P, Calonje E, Orchard G, Higgins E, Sherwood R, Russell-Jones R (2002) Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma. Br J Dermatol 146:832-835
2. Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E (1989) Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol 69:120-124
3. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA, et al (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164:193-203
4. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17:990-997
5. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11:8606-8614
6. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
7. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M (2005) Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65:11185-11192
8. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U (1994) Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54:5695-5701
9. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, Martin R (1989) Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 49:5358-5363
10. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57:3149-3153
11. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate ML, Galdeano AG, Izu R, Diaz-Ramon L, Raton JA, et al (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847-852
12. Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res 15:515-522
13. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L (2006) Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg 59:961-968
14. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic Activation of KIT in Distinct Subtypes of Melanoma. J Clin Oncol 14:14
15. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147
16. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M (2003) Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 162:1951-1960
17. Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23:1473-1482
18. Deichmann M, Brenner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-beta, melanoma-inhibiting activity and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17:1891-1896
19. Deichmann M, Kahle B, Moser K, Wacker J, Wust K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91:699-702
20. Dippel E, Goerdt S, Assaf C, Stein H, Orfanos CE (1997) Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet 350:1776-1777
21. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67-68
22. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515-1520
23. Fecker LF, Geilen CC, Tchernev G, Trefzer U, Assaf C, Kurbanov BM, Schwarz C, Daniel PT, Eberle J (2006) Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 126:1366-1371
24. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000) Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6:3614-3620
25. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195:530-536
26. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78:40-45
27. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS (2004) Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64:2245-2250
28. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737-1745
29. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, et al (2005) Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23:8048-8056
30. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924-928
31. Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R (2004) Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 209:296-300
32. Hauschild A, Engel G, Brenner W, Glaeser R, Moenig H, Henze E, Christophers E (1999a) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140:1065-1071
33. Hauschild A, Engel G, Brenner W, Glaeser R, Monig H, Henze E, Christophers E (1999b) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338-344
34. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, Ito S, Ono T (1997) Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58-62
35. Janku F, Novotny J, Julis I, Julisova I, Pecen L, Tomancova V, Kocmanova G, Krasna L, Krajsova I, Stork J, et al (2005) KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 15:251-256
36. Jury CS, McAllister EJ, MacKie RM (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143:269-274
37. Keehn CA, Smoller BR, Morgan MB (2004) Ets-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 31:8-13
38. Kerkela E, Ala-aho R, Klemi P, Grenman S, Shapiro SD, Kahari VM, Saarialho-Kere U (2002) Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 198:258-269
39. Klemke CD, Goerdt S, Schrama D, Becker JC (2006) New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 4:395-406
40. Klemke CD, Mansmann U, Poenitz N, Dippel E, Goerdt S (2005) Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sezary syndrome. Br J Dermatol 153:118-124
41. Koseki S, Aoki T, Ansai S, Hozumi Y, Mitsuhashi Y, Kondo S (1999) An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis. J Dermatol 26:416-422
42. Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU (2001) Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 84:72-79
43. Krähn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU (2001) S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 21:1311-1316
44. Mangini J, Li N, Bhawan J (2002) Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol 24:270-281
45. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M (1999) Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30:339-344
46. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23:5088-5093
47. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, Dummer R (2006) p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 118:2262-2268
48. Mikhail M, Velazquez E, Shapiro R, Berman R, Pavlick A, Sorhaindo L, Spira J, Mir C, Panageas KS, Polsky D, et al (2005) PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 11:5153-5157
49. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739-744
50. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405-1409
51. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19:239-247
52. Niezabitowski A, Czajecki K, Rys J, Kruczak A, Gruchala A, Wasilewska A, Lackowska B, Sokolowski A, Szklarski W (1999) Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70:150-160
53. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S (2005) High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11:5158-5166
54. Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S (2005) Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. Cancer 103:1693-1700
55. Niu Y, Liu F, Zhou Z, Wang H (2002) Expression of CD44V6 and PCNA in squamous cell carcinomas. Chin Med J (Engl) 115:1564-1568
56. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 12:325-334
57. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V, Suter L (2001) Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 145:203-209
58. Ottaiano A, Leonardi E, Simeone E, Ascierto PA, Scala S, Calemma R, Bryce J, Caraco C, Satriano RA, Gianfranco N, et al (2006) Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 33:150-155
59. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Pahlman S (1987) S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18:911-918
60. Petter G, Haustein UF (2000) Histologic subtyping and malignancy assessment of cutaneous squamous cell carcinoma. Dermatol Surg 26:521-530
61. Polsky D, Melzer K, Hazan C, Panageas KS, Busam K, Drobnjak M, Kamino H, Spira JG, Kopf AW, Houghton A, et al (2002) HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 94:1803-1806
62. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100:580-585
63. Redondo P, Lloret P, Idoate M, Inoges S (2005) Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30:541-545
64. Rodriguez-Rodriguez L, Sancho-Torres I, Gibbon DG, Watelet LF, Mesonero C (2000) CD44-9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva. J Soc Gynecol Investig 7:70-75
65. Roesch A, Becker B, Meyer S, Wild P, Hafner C, Landthaler M, Vogt T (2005) Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 18:1249-1257
66. Saalbach A, Wetzel A, Haustein UF, Sticherling M, Simon JC, Anderegg U (2005) Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene 24:4710-4720
67. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835-1841
68. Scheibenbogen C, Mohler T, Haefele J, Hunstein W, Keilholz U (1995) Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res 5:179-181
69. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006a) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106:1130-1139
70. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006b) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24:798-804
71. Schultz ES, Diepgen TL, Von Den Driesch P (1998) Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138:426-430
72. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72:3091-3098
73. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R (2005) Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 15:199-204
74. Stahlecker J, Gauger A, Bosserhoff A, Buettner R, Ring J, Hein R (2000) MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 20:5041-5044
75. Stoitchkov K, Letellier S, Garnier JP, Bousquet B, Tsankov N, Morel P, Ghanem G, Le Bricon T (2003) Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res 13:587-593
76. Suiqing C, Min Z, Lirong C (2005) Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 32:354-360
77. Swart GW, Lunter PC, Kilsdonk JW, Kempen LC (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Metastasis Rev 24:223-236
78. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, Topuz E (2004) Serum bcl-2 and survivin levels in melanoma. Melanoma Res 14:543-546
79. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20:2530-2536
80. Udart M, Utikal J, Krahn GM, Peter RU (2001) Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3:245-254
81. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D (2005a) Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117:825-830
82. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A, Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, et al (2005b) Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 92:1398-1405
83. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001a) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577-583
84. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001b) Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282-1286
85. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR (2005) Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 125:526-531
86. Vonderheid EC, Zhang Q, Lessin SR, Polansky M, Abrams JT, Bigler RD, Wasik MA (1998) Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 38:207-220
87. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37:1629-1634
88. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B (2006) Metallothionein - overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br J Cancer 94:835-841
89. Westhoff U, Fox C, Otto FJ (1998) Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res 18:3789-3792
90. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785
91. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G (1997) Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57:5073-5076
92. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, et al (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472-482
93. Wu H, Barusevicius A, Babb J, Klein-Szanto A, Godwin A, Elenitsas R, Gelfand JM, Lessin S, Seykora JT (2005) Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential. J Cutan Pathol 32:125-130
94. Yamada M, Yanaba K, Takehara K, Sato S (2005) Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma. Arch Dermatol Res 297:256-260